Route of administration-dependent anti-inflammatory effect of liposomal alendronate

Elran Haber, Haber E, E Haber, Afergan E, Eyal Afergan, E Afergan, H. Epstein, Epstein H, Dikla Gutman, D Gutman, Gutman D, N Koroukhov, Nickolay Koroukhov, Koroukhov N, M. Ben-David, Ben-David M, Schachter M, M. Schachter, G Golomb, Gershon Golomb
Journal of controlled release : official journal of the Controlled Release Society · 2010 · vol. 148(2) , pp. 226–233 · doi:10.1016/j.jconrel.2010.08.030 · PMID:20813142 · W2086783217
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-27 ⓘ

Liposomal alendronate's anti-inflammatory effects on restenosis and endometriosis depend on administration route, with IV/IP LA inhibiting restenosis via monocyte depletion but only IP LA inhibiting endometriosis by depleting local and circulating monocytes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Innate immunity and inflammation are of major importance in various pathological conditions. Intravenous (IV) and intraperitoneal (IP) liposomal alendronate (LA) treatments have been shown to deplete circulating monocytes and peritoneal macrophages resulting in the inhibition of restenosis and endometriosis (EM), respectively. Nevertheless, the correlation between the extent of circulating monocyte depletion and liposome biodistribution is unknown, and the route of administration-dependent bioactivity in restenosis and EM has not been determined. We found that, LA treatment resulted in a dose-response modified biodistribution following both IV and IP administrations. The biodistribution of high-dose LA (10mg/kg), but not that of the low-dose (1mg/kg), was similar in healthy and diseased animals. It is concluded that LA impedes its own elimination from the circulation by depleting circulating monocytes and/or inhibiting their endocytic activity, in a dose-dependent manner. Both IV and IP administration of LA mediated by the partial and transient depletion of circulating monocytes effected inhibition of restenosis. Inhibition of EM was effected only by IP administration, which depleted both intraperitoneal and circulating monocytes. Thus, EM should be considered as a local inflammatory condition with systemic manifestations as opposed to restenosis, a systemic inflammatory disease.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Alendronate Anti-Inflammatory Agents Carotid Stenosis Endometriosis Alendronate Alendronate Alendronate Alendronate Animals Anti-Inflammatory Agents Anti-Inflammatory Agents Anti-Inflammatory Agents Anti-Inflammatory Agents Carotid Stenosis Carotid Stenosis Carotid Stenosis Chemistry, Pharmaceutical Disease Models, Animal Dose-Response Relationship, Drug Drug Compounding

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (58)

Source provenance

europepmc
last seen: 2026-08-23T09:30:01.253652+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK